A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig ...
Jan 30, 2017 · Objective. To compare the efficacy of abatacept to that of placebo for the treatment of Takayasu arteritis (TAK). Methods. In this multicenter trial, patients with newly diagnosed or relapsing TAK were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily.